Journals / Klimik Dergisi / 2018 / Cilt: 31 - Sayı: 2

Investigation of Hepatitis B Serology in Oncological Patients Receiving Chemotherapy

Kemoterapi Uygulanan Onkoloji Hastalarında Hepatit B Serolojisi

Pages
101–105
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed to increase awareness on this issue.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we evaluated whether HBV serology had been investigated before chemotherapy or not, and whether antiviral prophylaxis had been given or not to hepatitis B surface antigen (HBsAg)- and/or hepatitis B core antibody (anti- HBc IgG)-positive patients.
📊
Key Findings & Data:Methods: The study was planned retrospectively between May 2012 and April 2014.
💡
Conclusion & Impact:Further studies are needed to increase awareness on this issue.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we evaluated whether HBV serology had been investigated before chemotherapy or not, and whether antiviral prophylaxis had been given or not to hepatitis B surface antigen (HBsAg)- and/or hepatitis B core antibody (anti- HBc IgG)-positive patients. Methods: The study was planned retrospectively between May 2012 and April 2014. Patients who were followed in the oncology outpatient clinic and whose chemotherapy was initiated due to solid organ malignancy were included. IBM SPSS Statistics for Windows. Version 22.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, USA) program was used for statistical evaluation. Results: As a result of the study, the data of 1476 regular follow- up patients were reached. 49.4% of the patients were male. The mean age was calculated as 60.6±13.3. Of the patients, 864 (58.1%) were screened for HBV infection. For screening, HBsAg and anti-HBs were used together in 53.8% of the patients, and only HBsAg was used in 4.3% of them. Anti-HBc IgG was not used in any of the patients. HBsAg positivity was 3.5% and anti- HBs positivity was 37.9% of the screened patients. Of HBsAgpositive patients, 74.1% was started prophylactic antivirals (entecavir in 2 patients, lamivudine in 21 patients), whereas eight patients did not receive prophylaxis. Conclusions: It was determined that HBV serology was investigated in most of the patients who would receive chemotherapy but the serologic parameters used for investigation were not suitable in most cases. Further studies are needed to increase awareness on this issue.

Özet

Amaç: Bu çalışmada, kemoterapi başlanacak olan onkoloji hastalarında,kemoterapi öncesi HBV serolojisinin araştırılıp araştırılmadığı;hepatit B yüzey antijeni (HBsAg) ve/veya hepatit B korantikoru (anti-HBc IgG) saptanan olgularda antiviral profilaksibaşlanıp başlanmadığı değerlendirildi.Yöntemler: Çalışma Mayıs 2012- Nisan 2014 tarihleri arasında,retrospektif olarak yapıldı. Çalışmaya onkoloji polikliniğindetanı ve tedavi alarak takip edilen ve solid organ malignitesi nedeniylekemoterapi başlanan hastalar dahil edildi. İstatistikseldeğerlendirme için IBM SPSS Statistics for Windows. Version22.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk,NY, ABD) programı kullanıldı.Bulgular: Çalışma sonucunda düzenli olarak takip edilen 1476hastanın verilerine ulaşıldı. Hastaların %49.4’ü erkek, %50.6’sıkadın olup ortalama yaş 60.6 ±13.3 olarak hesaplandı. Hastaların864 (%58.1)’ü HBV infeksiyonu açısından taranmıştı. Taramaiçin hastaların %53.8’inde HBsAg ve anti-HBs birlikte,%4.3’ünde ise yalnızca HBsAg kullanılmıştı. Anti-HBc IgG hiçbirhastada araştırılmamıştı. Tarama yapılan hastaların %3.5’indeHBsAg pozitifliği ve %37.9’unda anti-HBs pozitifliği tespit edilmişti.HBsAg-pozitif hastalardan %74.1’ine antiviral profilaksi(2 hastada entekavir, 21 hastada lamivudin) başlanmış; sekizhasta ise antiviral profilaksi almamıştı.Sonuçlar: Çalışma sonucunda kemoterapi alacak hastaların çoğundaHBV serolojisi araştırılmış olmakla birlikte kullanılan serolojikparametrelerin, çoğunlukla uygun olmadığı saptanmıştır.Bu konudaki farkındalığın artırılması için daha fazla çalışmagereklidir.

🔖

Cite This Article

UYSAL, M., TÜRKOĞLU, E., DEMİRTÜRK, N. (2022). Investigation of Hepatitis B Serology in Oncological Patients Receiving Chemotherapy. Klimik Dergisi, Cilt: 31 - Sayı: 2, 101–105. https://ajindex.com/articles/573531

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004; 90(7): 1306-11. [CrossRef] 2. Sarin SK, Kumar M, Lau GK, et al. Guidelines: Asian pasific clinical practice guidelines on the manangement of hepatitis B: a 2015 update. Hepatol Int. 2016; 10(1): 1-98. [CrossRef] 3. Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol. 2010; 28(19): 3199-202. [CrossRef] 4. Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2012; 10(11): 1412-45. [CrossRef] 5. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22(6): 59-63. [CrossRef] 6. European Association for the Study of the Liver, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2): 370-98. [CrossRef] 7. Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661-2. [CrossRef] 8. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008; 57(RR-8):1–20. 9. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009; 150(2):104–10. [CrossRef] 10. Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer. 2013; 13:534. [CrossRef] 11. Lee RS, Bell CM, Singh JM, Hicks LK. Hepatitis B screening before chemotherapy: a survey of practitioners’ knowledge, beliefs, and screening practices. J Oncol Pract. 2012; 8(6): 325-8. [CrossRef] 12. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62